As the global burden of chronic diseases continues to grow, cardiovascular disease has become one of the leading threats to human health. Dyslipidemia, a key risk factor for cardiovascular diseases such as atherosclerosis and coronary heart disease, has become increasingly important for early detection and intervention. Against this backdrop, the lipid testing industry is experiencing a new round of technological innovation and market expansion, with demand particularly growing in emerging economies and developing countries.
From an industry perspective, the aging of the global population and the trend toward Westernized lifestyles are driving the rising prevalence of dyslipidemia. According to the World Health Organization, approximately 39% of adults worldwide have dyslipidemia, with this proportion exceeding 50% in some high-income countries. At the same time, public health policies around the world are increasingly prioritizing disease prevention. For example, authoritative organizations such as the American Heart Association and the European Society of Cardiology have included regular lipid screening as a routine management measure for high-risk populations. These factors have collectively driven the evolution of lipid testing technology, evolving from traditional fasting venous blood testing to more convenient methods such as point-of-care testing (POCT) and dry-type biochemical analysis.
The significance of the blood lipid testing industry lies not only in its clinical value but also in its profound impact on global economic and social development. On the one hand, accurate blood lipid data can help medical institutions develop personalized treatment plans, reduce the incidence of cardiovascular events, and thus reduce medical expenses. On the other hand, the widespread use of portable home testing devices has brought health management to a more advanced level, enabling consumers to proactively monitor their blood lipid levels and foster a preventative approach to health.
In terms of foreign trade, the industry's technology exports and equipment trade not only meet the international market's demand for high-quality medical products but also provide important support for global public health cooperation. In the future, with the integration and application of artificial intelligence and big data technologies, the blood lipid testing industry is expected to further advance towards intelligent and precise testing, contributing to the building of a global health and well-being community for all mankind.